According to Moderna, the RSV vaccination was 83.7% efficient at preventing lower respiratory tract disease in adults 60 and older, which is defined as having two or more symptoms.
According to the CDC, RSV infections cause 60,000 to 120,000 hospital admissions and between 6,000 and 10,000 deaths in senior citizens each year.
The RSV vaccine from Moderna employs the same messenger RNA technology as their popular Covid injections.
On Tuesday, Moderna claimed that their vaccination against the respiratory syncytial virus is successful in avoiding illness in older persons.
According to the Boston biotech business, the vaccine was 83.7% effective at preventing lower respiratory tract disease in adults 60 and older, defined as two or more symptoms. When three or more symptoms were present, it was 82.4% effective at preventing lower respiratory tract illness.
In the first half of this year, Moderna said it intends to submit an application for Food and Drug Administration approval. The RSV vaccine has not yet received FDA approval.
According to the Centers for Disease Control and Prevention, RSV infections kill between 6,000 and 10,000 older persons each year and cause 60,000 to 120,000 hospitalizations.
Children and older adults in the U.S. experienced an abnormally severe RSV season last fall as a result of widespread abandonment of public health initiatives introduced in response to the Covid-19 pandemic, including as masking and social seclusion.
The company’s successful Covid injections and Moderna’s RSV vaccine both utilise the same messenger RNA technology. The Covid vaccination made Moderna a household name and brought in unexpected riches, but it is now the only product the company sells and demand for it is dwindling.
The Boston-based biotech company is under increasing pressure to show that other medications in its pipeline will be a success when they are released into the market. According to Morgan Stanley, the adult RSV vaccine industry is worth $7 billion to $10 billion.